Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 4/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL6254291 | 1.00 | ADK (0.70) | ADKHTTXDHNPC1ALDH1A1 | |
| SCHEMBL4876854 | 0.98 | ADK (0.72) | ADKHTTXDHNPC1ALDH1A1 | |
| Acetic Acid SCHEMBL4894479 | 0.84 | ADK (0.52) | ADKHTTXDHNPC1ALDH1A1 | |
| SCHEMBL12870514 | 0.82 | ADK (0.83) | ADKHTTNPC1ALDH1A1MAPT | |
| SCHEMBL4873358 | 0.82 | ADK (1.00) | ADKHTTNPC1ALDH1A1 | |
| SCHEMBL25391024 | 0.82 | ADK (1.00) | ADKHTTNPC1ALDH1A1 | |
| SCHEMBL14317644 | 0.82 | ADK (1.00) | ADKHTTNPC1ALDH1A1 | |
| SCHEMBL25390216 | 0.82 | ADK (1.00) | ADKHTTNPC1ALDH1A1 | |
| SCHEMBL14003840 | 0.82 | ADK (1.00) | ADKHTTNPC1ALDH1A1 | |
| SCHEMBL25390414 | 0.82 | ADK (1.00) | ADKHTTNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449570-B2 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | PTC THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-7291603-B2 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20060166926-A1 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
| US-20040067900-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166926-A1 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | NSUN2, UPF1, NSUN3 | ADK 523/4885HTT 68/4885XDH 896/4885 |
| US-20040067900-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | NSUN2, RNMT, NSUN3 | ADK 198/4885HTT 174/4885XDH 1126/4885 |
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | NSUN2, RNMT, NSUN3 | ADK 198/4885HTT 174/4885XDH 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.